Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.54%0700.HK-5.72%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK+0.14%ORCL-0.97%3988.HK+0.12%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.22%0857.HK-0.49%UNH-10.21%1288.HK-1.06%PM-0.85%0005.HK-2.31%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.61%AUDUSD-1.43%AUDCAD-0.96%EURAUD+0.95%AUDCHF-0.94%GBPAUD+0.87%AUDNZD-0.82%NZDJPY-0.81%GBPJPY-0.75%EURJPY-0.70%CHFJPY-0.67%CADJPY-0.66%NZDUSD-0.61%GBPUSD-0.55%AUDSGD-0.54%USDCHF+0.52%AUDDKK-0.50%EURUSD-0.50%USDCAD+0.49%AUDNOK-0.43%GBPTRY+0.41%GBPHKD+0.32%USDMXN+0.31%NZDMXN+0.29%GBPMXN-0.28%USDZAR+0.25%USDTHB+0.22%USDTRY+0.21%USDJPY-0.20%EURZAR+0.20%GBPZAR+0.16%USDILS+0.16%NZDCAD-0.15%CHFNOK+0.14%NZDCHF-0.13%CHFSEK+0.12%USDNOK+0.12%USDCNH-0.12%EURNZD+0.12%NOKJPY-0.10%USDSEK+0.10%USDPLN+0.10%EURCNH-0.08%GBPCAD-0.08%GBPSGD-0.07%PLNJPY-0.07%GBPNZD+0.07%EURGBP+0.06%EURNOK+0.06%EURHKD-0.06%USDDKK+0.05%EURSEK+0.05%EURPLN+0.04%EURSGD-0.04%EURCZK+0.04%USDCOP-0.04%CHFSGD+0.03%GBPCHF-0.03%CADCHF+0.03%EURCHF+0.02%SGDJPY+0.02%EURCAD-0.02%USDSGD+0.01%USDHKD-0.01%NZDSGD+0.01%EURDKK0.00%UKOIL+1.12%USOIL+0.92%GAGUSD+0.68%XAGUSD+0.68%COTTON+0.66%XNGUSD-0.65%GAUUSD+0.55%XAUUSD+0.55%HG1+0.43%W1-0.23%C1-0.17%XPTUSD+0.03%BTCUSD-3.25%ETHUSD+57.77%USDTUSD-0.02%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.83%ZECUSDT-6.15%XMRUSDT-1.51%DOGEUSD+55.95%LINKUSD-3.05%XLMUSD-3.56%BCHUSDT-3.26%LTCUSD+47.50%UNIUSD-2.39%SUIUSD-2.95%TONUSD+59.18%HBARUSDT-4.76%TAOUSDT-2.95%AAVEUSD-3.05%ONDOUSDT-5.00%ICPUSDT-2.61%DOTUSDT-3.63%WLDUSDT-3.57%ARBUSDT-4.99%ATOMUSDT-2.54%INJUSDT-6.72%STXUSDT-2.75%PYTHUSDT-1.30%TIAUSDT-3.37%FETUSDT-3.86%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.14%OPUSDT-2.63%IOTAUSDT-2.39%POLUSDT-1.66%WIFUSDT-2.98%AXSUSDT-2.47%EOSUSDT-4.38%IMXUSDT-3.36%FARTCOINUSDT-5.56%GALAUSDT-2.38%DYDXUSDT-2.58%ORDIUSDT-2.73%NOTUSDT+0.86%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.54%0700.HK-5.72%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK+0.14%ORCL-0.97%3988.HK+0.12%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.22%0857.HK-0.49%UNH-10.21%1288.HK-1.06%PM-0.85%0005.HK-2.31%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.61%AUDUSD-1.43%AUDCAD-0.96%EURAUD+0.95%AUDCHF-0.94%GBPAUD+0.87%AUDNZD-0.82%NZDJPY-0.81%GBPJPY-0.75%EURJPY-0.70%CHFJPY-0.67%CADJPY-0.66%NZDUSD-0.61%GBPUSD-0.55%AUDSGD-0.54%USDCHF+0.52%AUDDKK-0.50%EURUSD-0.50%USDCAD+0.49%AUDNOK-0.43%GBPTRY+0.41%GBPHKD+0.32%USDMXN+0.31%NZDMXN+0.29%GBPMXN-0.28%USDZAR+0.25%USDTHB+0.22%USDTRY+0.21%USDJPY-0.20%EURZAR+0.20%GBPZAR+0.16%USDILS+0.16%NZDCAD-0.15%CHFNOK+0.14%NZDCHF-0.13%CHFSEK+0.12%USDNOK+0.12%USDCNH-0.12%EURNZD+0.12%NOKJPY-0.10%USDSEK+0.10%USDPLN+0.10%EURCNH-0.08%GBPCAD-0.08%GBPSGD-0.07%PLNJPY-0.07%GBPNZD+0.07%EURGBP+0.06%EURNOK+0.06%EURHKD-0.06%USDDKK+0.05%EURSEK+0.05%EURPLN+0.04%EURSGD-0.04%EURCZK+0.04%USDCOP-0.04%CHFSGD+0.03%GBPCHF-0.03%CADCHF+0.03%EURCHF+0.02%SGDJPY+0.02%EURCAD-0.02%USDSGD+0.01%USDHKD-0.01%NZDSGD+0.01%EURDKK0.00%UKOIL+1.12%USOIL+0.92%GAGUSD+0.68%XAGUSD+0.68%COTTON+0.66%XNGUSD-0.65%GAUUSD+0.55%XAUUSD+0.55%HG1+0.43%W1-0.23%C1-0.17%XPTUSD+0.03%BTCUSD-3.25%ETHUSD+57.77%USDTUSD-0.02%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.83%ZECUSDT-6.15%XMRUSDT-1.51%DOGEUSD+55.95%LINKUSD-3.05%XLMUSD-3.56%BCHUSDT-3.26%LTCUSD+47.50%UNIUSD-2.39%SUIUSD-2.95%TONUSD+59.18%HBARUSDT-4.76%TAOUSDT-2.95%AAVEUSD-3.05%ONDOUSDT-5.00%ICPUSDT-2.61%DOTUSDT-3.63%WLDUSDT-3.57%ARBUSDT-4.99%ATOMUSDT-2.54%INJUSDT-6.72%STXUSDT-2.75%PYTHUSDT-1.30%TIAUSDT-3.37%FETUSDT-3.86%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.14%OPUSDT-2.63%IOTAUSDT-2.39%POLUSDT-1.66%WIFUSDT-2.98%AXSUSDT-2.47%EOSUSDT-4.38%IMXUSDT-3.36%FARTCOINUSDT-5.56%GALAUSDT-2.38%DYDXUSDT-2.58%ORDIUSDT-2.73%NOTUSDT+0.86%RONINUSDT-2.92%
RP

Regeneron Pharmaceuticals, Inc. (REGN)

NASDAQ • Healthcare

$945.53
-$12.23 (-1.3%)
Market closed

November 18, 2026 at 21:00 UTC

Open$957.25
Day Range$943.26 - $972
Avg. Volume (3M)1M
Market Cap$97.7B
P/E Ratio20.1
52 Week Range
$591.52$991.73
Next EarningsIn 70 daysJan 28, 2027

Interactive Chart

02:13:14 UTC

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$5.1B100%
Gross Profitminus cost of goods$4.5B89%
Operating Incomeminus R&D and overhead$2B40%
Net Incomeminus taxes and the rest$1.9B38%

In plain terms: out of every $100 in revenue, Regeneron Pharmaceuticals, Inc. keeps $38 as net profit.

Fundamentals & Financials

Revenue (TTM)
$16.8B
Net Income (TTM)
$4.8B
EPS (TTM)
$46.98
ROA (TTM)
10.85%
Current Ratio
3.35
Dividend Yield
0.12%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+6.3%Q2 2026$9.47
+40.6%Q3 2026$14.29
+21.6%Q4 2026$20.07
Next

Jan 28

in 70 daysQ1 2027

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Beat +21.6%

Regeneron Pharmaceuticals beat expectations on both the top and bottom line in the third fiscal quarter of 2026, reported October 30, 2026, with adjusted EPS of $20.07 topping the $16.51 estimate (+21.6%) and revenue of $5.116 billion topping the $4.584 billion estimate (+11.6%). Revenue rose ~36% to about $5.1 billion (up from roughly $3.8 billion a year ago), while net income increased ~34% to nearly $1.9 billion (up from about $1.5 billion a year ago), alongside adjusted EPS up ~70% from $11.83. Profitability remained high in the quarter, with gross margin at roughly 89% and operating margin at about 40%, as gross profit reached around $4.5 billion and operating income came in near $2.0 billion. The company generated operating cash flow of about $1.8 billion and returned cash through roughly $399.7 million of share repurchases and about $95.7 million of dividends. For the next period, consensus calls for EPS of $20.87 on revenue of $5.752 billion.

View full earnings history

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. develops and markets biologic medicines as a biotechnology company listed on NASDAQ under REGN. Its portfolio spans eye disease, immunology, oncology, cardiovascular and infectious-disease therapies, and it generated $14.3 billion of revenue in FY2025 through a portfolio of marketed drugs and clinical-stage product candidates.

Name
Regeneron Pharmaceuticals, Inc.
CEO
Leonard S. Schleifer
Industry
Healthcare
Year Founded
1988
Employees
15,410

Today's Snapshot

AI-generated

REGN closed 1.3% below yesterday's close, in line with a weaker sector. Trading was lighter than usual, with volume about two-thirds of its usual level. Regeneron won European approval to offer flexible dosing for Libtayo, its cancer drug.

Trading Volume

Below 10d avg (982.2K)

672.9K

vs S&P 500 Today

Underperforming Market

-1.02%

Updated: November 18, 2026 at 21:15 UTC

Technical Indicators

6 Buy2 Neutral0 Sell
REGN exhibits a robust bullish profile with a strong ADX confirming trend strength and positive momentum signaled by a sizable MACD reading and supportive shorter-term moving averages. The stock is trading materially above its long-term averages, and on-balance volume is positive, suggesting buying participation has accompanied the advance. Volatility is moderate for the share price and Bollinger width is steady, while the classic pivot around 956.7 now projects as near-term resistance above the current level. Technical takeaway: Strong Buy.
All signals
  • EMA (5 indicators)$773.10 - $936.76
    Buy
  • RSI (14)64.39
    Neutral
  • Stochastic %K (14, 3, 3)76.71
    Neutral
  • MACD Level (12, 26)40.55
    Buy
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.